Polymeric nanoparticles

Why use polymeric nanoparticles?

Polymeric nanoparticles serve as drug delivery carriers for active pharmaceutical ingredients (APIs). They typically range up to several hundred nanometers in diameter and are engineered from (biocompatible) polymers.

Their small size facilitates efficient cellular uptake, while the broad scope of polymers allows for tailored properties to ensure optimal drug release profiles and target specificity. Polymeric nanoparticles also offer versatility and can accommodate a wide range of therapeutic payloads, including small molecules, nucleic acids and proteins.

Experts in polymeric nanoparticle development

Our team of polymer experts crafts your polymeric nanoparticles. With years of experience in the synthesis and self-assembly of polymers, we can bring your product from a small-scale procedure to pilot-scale production.

We have experience in polymeric nanoparticle developments using a variety of polymers, such as block copolymers, cross-linked polymers and dendrimers.

Our analytical capabilities

Our team of analytical experts has extensive experience with various polymeric nanoparticles, including those from synthetic copolymers (e.g., PEG, PLA) or biopolymers (e.g., carbohydrates, proteins, polypeptides). Utilizing chromatographic and spectroscopic techniques, we quantify and determine (bio)polymer molecular weight distribution and various types of APIs, such as small-molecule drugs, peptides and oligonucleotides.

Additionally, we can determine critical characteristics of polymeric nanoparticles, such as particle size distribution, morphology (e.g., spherical or rod-like structures, micelles), surface charge and in-vitro release. Our analytical solutions offer comprehensive insights to support the development of polymeric nanoparticle formulations for various applications.

A more comprehensive list of characterization assessments provided at Ardena:

Appearance: Visual
Identity: FT-IR, NMR
Identification and quantification of (encapsulated) API and related impurities:
- Small-molecule drugs: LC-UV/CAD/MS
- Peptide/proteins: LC-UV/MS, AAA
- Oligonucleotides and mRNA: IPLC-UV/MS, qPCR, CGE (Fragment Analyzer), RiboGreen
Quantification of polymers: LC-UV/CAD, GPC, qNMR
Molecular weight distribution of polymers: GPC, AF4/SEC-MALS
Particle size distribution: DLS, AF4/SEC-MALS, TEM
Morphology: AF4/SEC-MALS, TEM
Surface properties: ELS (zeta potential)
Elemental impurities: ICP-MS
Residual solvents: GC-HS, GC-FID/MS
Solution properties (pH, osmolality), in vitro release, microbiological control: USP/Ph. Eur.

At Ardena, we stay at the forefront of technological advancements, continuously innovating to provide state-of-the-art solutions tailored to your unique project requirements. We value collaboration and work closely with clients to understand their needs and deliver the desired polymeric nanoparticle solutions.

Our experience and success stories

Our commitment to excellence is evident in our successful track record with polymeric nanoparticles. Ardena has played a pivotal role in advancing numerous projects, including:

Innovative polymerization systems:
Free radical polymerization systems, including custom monomer and initiator synthesis, for generating block copolymer architectures for drug encapsulation and delivery applications.

Advanced covalent functionalization methods:
Covalent functionalization approaches for dendritic nanoparticle-API conjugates through the application of click chemistry and the subsequent purification and formulation of the nanoparticle product.